Navigation Links
Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Date:7/11/2011

WORCESTER, Mass. and TORONTO, July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology.  Antigen Express, Inc., the Company's wholly-owned subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer.  AE37, an Ii-Key HER-2 hybrid, is currently the subject of a controlled, randomized, and single-blinded Phase II clinical trial in patients with HER-2 expressing breast cancer.

(Logo:  http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)

The publication, entitled "MHC Class II Epitope Nesting Modulates Dendritic Cell Function and Improves Generation of Antigen-Specific CD4 Helper T Cells," was published in the peer-reviewed Journal of Immunology (www.jimmunology.org).  A significant finding of the report, conducted in a mouse model, was that specific CD4+ T cell (T-helper) activation by Ii-Key hybrids excludes T regulatory (immune suppressor) cells.  T regulatory cells (immune suppressor) may hinder active immunotherapy of cancer.  The lack of activation of this cell type has been observed previously in clinical studies of AE37 (an Ii-Key-HER-2 hybrid), both in breast as well as prostate cancer patients.

The senior author of the study, Dr. Keith Knutson, has been one of the pioneers in the field of CD4+ T-helper cell stimulation for active immunotherapy of cancer.  "We are pleased to see this further confirmation of the potential of our technology," said Dr. Eric von Hofe, President of Antigen Express.  "Dr. Knutson has been one of the most important leaders in the field.  The confirmation of the lack of T reg
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
2. Generex Provides Clarification of Facts
3. Generex Announces Results of Annual Stockholders Meeting
4. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
5. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
6. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
7. Generex Announces $3.0 Million Capital Investment
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
10. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
11. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
(Date:8/28/2014)... Earlier this month, a report ... with the U.S. Air Force on the performance of ... that this type of fuel made from mustard seeds, ... important to America’s Eco friendly future. In fact, every ... to become independent of foreign oil over the next ...
(Date:8/27/2014)... Varian Medical Systems today broke ground ... Lake City manufacturing facility and allow for the consolidation ... create 1,000 new full time jobs in the state ... home to hardworking people with immense engineering and technical ... success in the manufacturing of our state-of-the-art X-ray technology,” ...
(Date:8/27/2014)... YORK , Aug. 27, 2014 /PRNewswire/ ... research report is available in its catalogue: ... 2014-2018 http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials are materials that are readily decomposed ... differs from conventional non-degradable packaging in terms ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... p.m. EDT -, VALENCIA, Calif., Aug. 11 ... for the second,quarter ended June 30, 2008., For ... $80.9,million, compared to $75.4 million for the second quarter ... and development,(R&D) expenses which totaled $67.6 million for this ...
... Aug. 11 Immtech Pharmaceuticals,Inc. (Amex: IMM ) ... 2008., For the three months ended June 30, ... three months ended June 30, 2007. The increase,was primarily ... from operations for the three months ended June 30, ...
... Informed Medical Communications,(IMC), a leading provider of ... position today on recent revisions,to the PhRMA Code. ... Code," noted Dr. Jaime Nguyen, Medical Director/Compliance Officer,for ... continually monitored,the compliance trends so that our services ...
Cached Biology Technology:MannKind Corporation Reports Second Quarter Financial Results 2MannKind Corporation Reports Second Quarter Financial Results 3MannKind Corporation Reports Second Quarter Financial Results 4MannKind Corporation Reports Second Quarter Financial Results 5MannKind Corporation Reports Second Quarter Financial Results 6Immtech Reports Fiscal First Quarter 2009 Results 2Immtech Reports Fiscal First Quarter 2009 Results 3Informed Medical Communications Highlights Opportunity in Revised PhRMA Code 2
(Date:8/28/2014)... Researchers at the University of Minnesota have developed an ... be used for muscle regeneration research as well as ... , The research is published in the current edition ... is no treatment for FSHD, which is thought by ... dystrophy. FSHD is an unusual genetic disorder because, unlike ...
(Date:8/28/2014)... unique method for delivering compounds that could ... and AIDS may be possible, thanks to ... Sciences., A semi-soft vaginal suppository made from ... with the antiviral drug Tenofovir provides a ... the spread of sexually transmitted infections during ...
(Date:8/28/2014)... More than 25 million kilometres of new roads will ... will slice into Earth,s last wildernesses, where they bring ... , Now, an ambitious study has created a ... to try to balance the competing demands of development ... an ,environmental-values, layer that estimates that natural importance of ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... This press release is available in Spanish ... losses to the atmosphere through volatilization also rise. ... (USDA) scientists found that herbicide volatilization consistently resulted in ... Agricultural Research Service (ARS) soil scientist Timothy ...
... it has not stopped her from working. Thanks in part ... her 13th year as an account executive for a firm ... are not as fortunate. In the United States, the ... as systemic sclerosis, is two to three times that of ...
... of scientists has produced a new map of the ... an ultra-nutritious potato that could help feed the world,s ... genome of the potato, the consortium has, for the ... Resulting insights into the growth and development of potatoes ...
Cached Biology News:Researchers study pesticide pathways into the atmosphere 2Scleroderma study identifies roadblocks to employment 2Scleroderma study identifies roadblocks to employment 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
Request Info...
... Nebulizers are available in two product models - ... two models is that the 6000AT+ includes a ... drier aerosol for improved detection limits and reduced ... a range of elements by 10-40 times. Note ...
Biology Products: